CStone Pharmaceuticals - Laporan Laba Rugi (TTM)

CStone Pharmaceuticals
HK ˙ SEHK ˙ KYG2588M1006
HK$ 12.33 ↑0.76 (6.57%)
2025-09-05
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi CStone Pharmaceuticals menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 519 1,039 1,079 1,118 681 244 335 426 454 481 481 481 472 464 460 457 432 407 305 202
Change (%) 100.33 3.82 3.68 -39.10 -64.21 37.40 27.22 6.49 6.10 -0.03 -0.03 -1.79 -1.82 -0.79 -0.79 -5.40 -5.71 -25.14 -33.58
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 121 241 257 273 190 107 138 168 186 203 211 218 189 160 147 134 150 167 197 227
Change (%) 100.00 6.46 6.07 -30.41 -43.69 28.79 22.35 10.29 9.33 3.77 3.64 -13.46 -15.55 -8.12 -8.83 12.50 11.11 17.99 15.25
% of Revenue 23.28 23.24 23.83 24.38 27.86 43.83 41.09 39.51 40.92 42.17 43.77 45.38 39.99 34.40 31.86 29.27 34.81 41.02 64.66 112.18
Gross Operating Profit 398 797 822 846 491 137 197 258 268 278 271 263 284 304 314 323 282 240 108 -25
Change (%) 100.44 3.02 2.94 -41.91 -72.14 44.13 30.62 4.01 3.86 -2.80 -2.88 7.90 7.32 3.05 2.96 -12.81 -14.69 -55.14 -122.89
% of Revenue 76.72 76.76 76.17 75.62 72.14 56.17 58.91 60.49 59.08 57.83 56.23 54.62 60.01 65.60 68.14 70.73 65.19 58.98 35.34 -12.18
SG&A 424 485 534 583 622 661 658 655 616 576 546 516 449 382 326 271 241 212 196 181
Change (%) 14.36 10.15 9.22 6.72 6.29 -0.49 -0.50 -5.99 -6.38 -5.25 -5.54 -12.97 -14.90 -14.55 -17.03 -10.94 -12.29 -7.15 -7.70
% of Revenue 81.73 46.65 49.50 52.14 91.37 271.37 196.53 153.71 135.69 119.74 113.48 107.22 95.02 82.37 70.94 59.33 55.86 51.96 64.45 89.55
R&D 1,480 1,405 1,389 1,373 1,339 1,305 1,182 1,059 836 614 574 534 518 501 468 407 252 124 143 163
Change (%) -5.12 -1.12 -1.13 -2.49 -2.55 -9.43 -10.41 -21.00 -26.58 -6.50 -6.95 -3.08 -3.18 -6.75 -12.89 -38.03 -50.90 15.64 13.53
% of Revenue 285.50 135.22 128.78 122.80 196.64 535.43 352.93 248.53 184.37 127.59 119.33 111.07 109.61 108.10 101.60 89.21 58.44 30.43 47.01 80.35
OpEx 2,025 2,131 2,180 2,229 2,151 2,073 1,978 1,882 1,638 1,394 1,331 1,268 1,156 1,043 941 812 644 503 537 571
Change (%) 5.23 2.30 2.25 -3.50 -3.62 -4.61 -4.83 -12.98 -14.91 -4.49 -4.70 -8.89 -9.75 -9.82 -13.69 -20.67 -21.96 6.83 6.39
% of Revenue 390.50 205.11 202.11 199.32 315.87 850.64 590.54 441.75 360.98 289.49 276.58 263.67 244.62 224.86 204.40 177.82 149.11 123.42 176.11 282.09
Operating Income -1,506 -1,092 -1,101 -1,111 -1,470 -1,829 -1,643 -1,456 -1,184 -912 -850 -787 -683 -579 -480 -355 -212 -95 -232 -369
Change (%) -27.51 0.86 0.85 32.36 24.45 -10.21 -11.37 -18.68 -22.96 -6.84 -7.34 -13.22 -15.24 -17.05 -26.05 -40.30 -55.04 143.33 58.90
% of Revenue -290.50 -105.11 -102.11 -99.32 -215.87 -750.64 -490.54 -341.75 -260.98 -189.49 -176.58 -163.67 -144.62 -124.86 -104.40 -77.82 -49.11 -23.42 -76.11 -182.09
Interest Expense -1 -1 -2 -3 -3 -2 -3 -3 -6 -8 -10 -11 -12 -12 -13 -14 -15 -15 -14 -14
Change (%) 54.21 74.20 42.60 -15.81 -18.78 16.48 14.15 92.18 47.97 17.33 14.77 1.77 1.74 10.47 9.48 3.05 2.96 -4.75 -4.99
% of Revenue -0.17 -0.13 -0.21 -0.29 -0.41 -0.92 -0.78 -0.70 -1.26 -1.76 -2.07 -2.37 -2.46 -2.55 -2.84 -3.13 -3.41 -3.72 -4.74 -6.78
Net Income -1,482 -1,221 -1,272 -1,324 -1,622 -1,920 -1,714 -1,508 -1,205 -903 -827 -750 -559 -367 -255 -142 -117 -91 -234 -377
Change (%) -17.64 4.20 4.03 22.53 18.39 -10.74 -12.03 -20.07 -25.10 -8.44 -9.22 -25.53 -34.28 -30.62 -44.14 -17.95 -21.88 156.72 61.05
% of Revenue -285.88 -117.54 -117.96 -118.36 -238.16 -787.84 -511.82 -353.92 -265.65 -187.53 -171.75 -155.97 -118.27 -79.17 -55.36 -31.17 -27.04 -22.40 -76.81 -186.23

Source: Capital IQ

Other Listings
DE:PH4 € 1.24
US:CSPHF
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista